NCT01883609View on ClinicalTrials.gov

A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Plasmodium Falciparum Malaria
Interventions
BIOLOGICAL

RTS,S/AS01B

Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01

BIOLOGICAL

ChAd63 ME-TRAP

ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp

BIOLOGICAL

MVA ME-TRAP

MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu

Trial Locations (4)

SO16 6YD

Wellcome Trust CRF, Southampton General Hospital, University of Southampton, Southampton

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford

SW7 2AZ

Infection and Immunity Section, Sir Alexander Fleming Building, Imperial College of Science, Technology and Medicine, London

W12 0HS

Hammersmith Hospital, Imperial College NHS Trust, London

All Listed Sponsors
lead

University of Oxford

OTHER

NCT01883609 - A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S | Biotech Hunter | Biotech Hunter